Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy
Among men, prostate cancer has a high prevalence, with relatively lower cancer-specific mortality risk compared to lung and colon cancer. Prostate-specific antigen (PSA) screening has increased prostate cancer awareness since its implementation as a screening tool almost 25 years ago, but, due to th...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/862639 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560368400990208 |
|---|---|
| author | Al B. Barqawi Kevin J. Krughoff Khadijah Eid |
| author_facet | Al B. Barqawi Kevin J. Krughoff Khadijah Eid |
| author_sort | Al B. Barqawi |
| collection | DOAJ |
| description | Among men, prostate cancer has a high prevalence, with relatively lower cancer-specific mortality risk compared to lung and colon cancer. Prostate-specific antigen (PSA) screening has increased prostate cancer awareness since its implementation as a screening tool almost 25 years ago, but, due to the largely indolent course of this disease and the unspecific nature of the PSA test, increased incidence has largely been associated with cancers that would not go on to cause death (clinically insignificant), leading to an overdiagnosis challenge and an ensuing overtreatment consequences. The overtreatment problem is exacerbated by the high risk of side effects that current treatment techniques have, putting patients’ quality of life at risk with little or no survival benefit. The goals of this paper are to evaluate the rise, prevalence, and impact of the overdiagnosis and ensuing overtreatment problems, as well as highlight potential solutions. In this effort, a review of major epidemiological and screening studies, cancer statistics from the advent of prostate-specific antigen screening to the present, and reports on patient concerns and treatment outcomes was conducted to present the dominant factors that underlie current challenges in prostate cancer treatment and illuminate potential solutions. |
| format | Article |
| id | doaj-art-0ea979ec2b9546db8ad5eaed63c7db63 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-0ea979ec2b9546db8ad5eaed63c7db632025-02-03T01:27:43ZengWileyAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/862639862639Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal TherapyAl B. Barqawi0Kevin J. Krughoff1Khadijah Eid2Division of Urology, University of Colorado Denver, Aurora, CO 80045, USADivision of Urology, University of Colorado Denver, Aurora, CO 80045, USADivision of Urology, University of Colorado Denver, Aurora, CO 80045, USAAmong men, prostate cancer has a high prevalence, with relatively lower cancer-specific mortality risk compared to lung and colon cancer. Prostate-specific antigen (PSA) screening has increased prostate cancer awareness since its implementation as a screening tool almost 25 years ago, but, due to the largely indolent course of this disease and the unspecific nature of the PSA test, increased incidence has largely been associated with cancers that would not go on to cause death (clinically insignificant), leading to an overdiagnosis challenge and an ensuing overtreatment consequences. The overtreatment problem is exacerbated by the high risk of side effects that current treatment techniques have, putting patients’ quality of life at risk with little or no survival benefit. The goals of this paper are to evaluate the rise, prevalence, and impact of the overdiagnosis and ensuing overtreatment problems, as well as highlight potential solutions. In this effort, a review of major epidemiological and screening studies, cancer statistics from the advent of prostate-specific antigen screening to the present, and reports on patient concerns and treatment outcomes was conducted to present the dominant factors that underlie current challenges in prostate cancer treatment and illuminate potential solutions.http://dx.doi.org/10.1155/2012/862639 |
| spellingShingle | Al B. Barqawi Kevin J. Krughoff Khadijah Eid Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy Advances in Urology |
| title | Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy |
| title_full | Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy |
| title_fullStr | Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy |
| title_full_unstemmed | Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy |
| title_short | Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy |
| title_sort | current challenges in prostate cancer management and the rationale behind targeted focal therapy |
| url | http://dx.doi.org/10.1155/2012/862639 |
| work_keys_str_mv | AT albbarqawi currentchallengesinprostatecancermanagementandtherationalebehindtargetedfocaltherapy AT kevinjkrughoff currentchallengesinprostatecancermanagementandtherationalebehindtargetedfocaltherapy AT khadijaheid currentchallengesinprostatecancermanagementandtherationalebehindtargetedfocaltherapy |